510(k) Report

De Novo · Granted

Granted

Revi System

DEN220073De NovoGranted Aug 16, 2023315-day reviewClass II21 CFR 876.5305

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Bluewind Medical, Ltd. · QXM Implanted Tibial Electrical Urinary Continence Device

Granted on Aug 16, 2023 as a new device type through De Novo after a 315-day review. 3 later devices descend from it.

Decided
Aug 16, 2023
Review
315 days
Class
Class II
Product code
QXM
Recalls
None

3 later devices descend from it, 1 citing it directly.

Descendants, by year cleared 2024: 1 descendant cleared2025: 1 descendant cleared2026: 1 descendant cleared2020202220242026
  1. This deviceDEN220073 Revi SystemBluewind Medical, Ltd. · 2023
  2. Descendant · cites it directly · 2 of its ownK240037 Revi™ SystemBluewind Medical, Ltd. · 2024
  3. Descendant · 2 generations on · 0 of its ownK253651 Revi SystemBluewind Medical, Ltd. · 2026
  4. Descendant · 2 generations on · 0 of its ownK252391 Revi SystemBluewind Medical, Ltd. · 2025

Most influential descendants

Showing 3 of 3 · See all
  • K240037Revi™ SystemBluewind Medical, Ltd. · 2024 · cites it directly2descendants
  • K253651Revi SystemBluewind Medical, Ltd. · 2026 · 2 generations on0descendants
  • K252391Revi SystemBluewind Medical, Ltd. · 2025 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)DEN220073Revi SystemBluewind Medical, Ltd.2023—
+1K240037Revi™ SystemBluewind Medical, Ltd.2024—
+2K253651Revi SystemBluewind Medical, Ltd.2026—
+2K252391Revi SystemBluewind Medical, Ltd.2025—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202410
202510
202610
FIG. 1 — Lineage of DEN220073, 2023–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA De Novo database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QXM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QXM device

  1. #1 K240037 Revi™ Systemscore 13.3 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

Does it have a predicate?

De Novo decisions do not claim a predicate device.

What descends from it? (3)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K240037Revi™ SystemBluewind Medical, Ltd.20242

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K240037 (Bluewind Medical, Ltd., 2024) has gone furthest, with 2 descendants of its own.

How does its category compare?

All QXM devices

QXM Implanted Tibial Electrical Urinary Continence Device: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · QXM

1in 2025

2023: 12024: 12025: 12026 (partial year): 1
2007high 1 (2023) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QXM

Too few QXM 510(k)s in any year since 2007 to give a median.

Recalls per year · QXM

No recall names QXM since 2007.

Adverse event reports per year · QXM

17in 2025

2024: 42025: 17
2007high 17 (2025) · low 0 (2007)2025

MAUDE reports naming product code QXM, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20231—00
20241—04
20251—017
20261—0—

What is it indicated for?

The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “DEN220073: Revi System.” Lineage record from FDA De Novo data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/DEN220073

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026